Delivery of doxorubicin loaded P18 conjugated-poly(2-ethyl-oxazoline)-DOPE nanoliposomes for targeted therapy of breast cancer
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 428, 115671
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activityBiomaterials, 2013
- Oral Delivery of Doxorubicin Using Novel Polyelectrolyte-Stabilized Liposomes (Layersomes)Molecular Pharmaceutics, 2012
- Identification Keratin 1 as a cDDP-resistant protein in nasopharyngeal carcinoma cell linesJournal of Proteomics, 2012
- Doxorubicin pathwaysPharmacogenetics and Genomics, 2011
- Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapyInternational Journal of Cancer, 2010
- Peptide Arrays for Screening Cancer Specific PeptidesAnalytical Chemistry, 2010
- Nanoparticle-based targeted drug deliveryExperimental and Molecular Pathology, 2009
- Mediating Tumor Targeting Efficiency of Nanoparticles Through DesignNano Letters, 2009
- Nanoparticle therapeutics: an emerging treatment modality for cancerNature Reviews Drug Discovery, 2008
- Activation of Bak, Bax, and BH3-only Proteins in the Apoptotic Response to DoxorubicinJournal of Biological Chemistry, 2002